RxDoctor Payments Data

Manoj Vora, MD

Internal Medicine · Lowville, NYNPI 1073510681

Payments from drug & device makers

$378in general payments, 2019–2025

Across 23 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$94
  • Lilly USA, LLC$93
  • Grifols USA, LLC$66
  • Johnson & Johnson$34
  • Pfizer$32
  • E.r. Squibb & Sons, L.L.C.$19
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$378 in reported general payments places this provider in the 55th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$91,374
Medicare patients
232
Services billed
983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide183$252,077
EliquisApixaban177$186,696
JardianceEmpagliflozin115$143,088
XareltoRivaroxaban78$102,156
JanuviaSitagliptin Phosphate35$37,655
FarxigaDapagliflozin Propanediol29$35,488
Breo ElliptaFluticasone/Vilanterol27$17,093
Incruse ElliptaUmeclidinium Bromide40$15,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,911
Combivent RespimatIpratropium/Albuterol Sulfate33$15,893
GlyxambiEmpagliflozin/Linagliptin17$13,795
Spiriva HandihalerTiotropium Bromide26$12,735
Praluent PenAlirocumab19$11,025
Fluticasone-SalmeterolFluticasone Propion/Salmeterol53$9,868
InvokanaCanagliflozin12$6,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$93$252,077183 claims
PfizerEliquis, Dilantin$32$190,434200 claims
Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi$94$172,775165 claims
Johnson & JohnsonXarelto, Invokana$34$109,03490 claims
AstraZenecaFarxiga, Symbicort$12$40,23343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Lowville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →